Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer

Yuichi Hisamatsu, Eriko Tokunaga, Nami Yamashita, Sayuri Akiyoshi, Satoko Okada, Yuichiro Nakashima, Kenji Taketani, Shinichi Aishima, Yoshinao Oda, Masaru Morita, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

14 引用 (Scopus)

抄録

Background: Determining the indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)-positive/HER2-negative breast cancer are difficult. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) are crucial for the hormone responsive phenotype of breast cancer. This study evaluated whether the expression of GATA-3 and FOXA1 is a prognostic and predictive marker of outcomes in patients with HR-positive/HER2-negative breast cancer. Methods: The expression of GATA-3 and FOXA1 was analyzed immunohistochemically in 214 patients with invasive breast cancer to evaluate the association with the clinicopathological features and the prognosis. Results: GATA-3 expression was positively correlated with FOXA1 expression (P < 0.0001). Both GATA-3 and FOXA1 were positively correlated with ER (P < 0.0001 each) and PR expression (P = 0.0001 and P = 0.0009, respectively), and inversely correlated with nuclear grade (P = 0.0002 and P = 0.0018, respectively) and Ki67 index (P = 0.0052 and P = 0.0049, respectively). Expression of GATA-3 and FOXA1 was associated with better prognosis. FOXA1 was an independent favorable prognostic marker in HR-positive/HER2-negative breast cancer. Disease-free survival rates were similar in patients with HR-positive/HER2-negative breast cancer and high FOXA1 expression given adjuvant hormone therapy (HT) alone and those given CT plus HT. Conclusion: GATA-3 and FOXA1 are associated with a less aggressive phenotype and a better prognosis in patients with HR-positive/HER2-negative breast cancer. FOXA1 may be useful in identifying those patients who may not require adjuvant CT.

元の言語英語
ページ(範囲)520-528
ページ数9
ジャーナルBreast Cancer
22
発行部数5
DOI
出版物ステータス出版済み - 9 7 2015

Fingerprint

Carrier Proteins
Hormones
Breast Neoplasms
Adjuvant Chemotherapy
Hepatocyte Nuclear Factor 3-alpha
GATA Transcription Factors
Phenotype
Disease-Free Survival
Survival Rate
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

これを引用

Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. / Hisamatsu, Yuichi; Tokunaga, Eriko; Yamashita, Nami; Akiyoshi, Sayuri; Okada, Satoko; Nakashima, Yuichiro; Taketani, Kenji; Aishima, Shinichi; Oda, Yoshinao; Morita, Masaru; Maehara, Yoshihiko.

:: Breast Cancer, 巻 22, 番号 5, 07.09.2015, p. 520-528.

研究成果: ジャーナルへの寄稿記事

Hisamatsu, Y, Tokunaga, E, Yamashita, N, Akiyoshi, S, Okada, S, Nakashima, Y, Taketani, K, Aishima, S, Oda, Y, Morita, M & Maehara, Y 2015, 'Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer', Breast Cancer, 巻. 22, 番号 5, pp. 520-528. https://doi.org/10.1007/s12282-013-0515-x
Hisamatsu, Yuichi ; Tokunaga, Eriko ; Yamashita, Nami ; Akiyoshi, Sayuri ; Okada, Satoko ; Nakashima, Yuichiro ; Taketani, Kenji ; Aishima, Shinichi ; Oda, Yoshinao ; Morita, Masaru ; Maehara, Yoshihiko. / Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. :: Breast Cancer. 2015 ; 巻 22, 番号 5. pp. 520-528.
@article{2e235f3dae024eb58104ee3dadc7e8b4,
title = "Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer",
abstract = "Background: Determining the indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)-positive/HER2-negative breast cancer are difficult. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) are crucial for the hormone responsive phenotype of breast cancer. This study evaluated whether the expression of GATA-3 and FOXA1 is a prognostic and predictive marker of outcomes in patients with HR-positive/HER2-negative breast cancer. Methods: The expression of GATA-3 and FOXA1 was analyzed immunohistochemically in 214 patients with invasive breast cancer to evaluate the association with the clinicopathological features and the prognosis. Results: GATA-3 expression was positively correlated with FOXA1 expression (P < 0.0001). Both GATA-3 and FOXA1 were positively correlated with ER (P < 0.0001 each) and PR expression (P = 0.0001 and P = 0.0009, respectively), and inversely correlated with nuclear grade (P = 0.0002 and P = 0.0018, respectively) and Ki67 index (P = 0.0052 and P = 0.0049, respectively). Expression of GATA-3 and FOXA1 was associated with better prognosis. FOXA1 was an independent favorable prognostic marker in HR-positive/HER2-negative breast cancer. Disease-free survival rates were similar in patients with HR-positive/HER2-negative breast cancer and high FOXA1 expression given adjuvant hormone therapy (HT) alone and those given CT plus HT. Conclusion: GATA-3 and FOXA1 are associated with a less aggressive phenotype and a better prognosis in patients with HR-positive/HER2-negative breast cancer. FOXA1 may be useful in identifying those patients who may not require adjuvant CT.",
author = "Yuichi Hisamatsu and Eriko Tokunaga and Nami Yamashita and Sayuri Akiyoshi and Satoko Okada and Yuichiro Nakashima and Kenji Taketani and Shinichi Aishima and Yoshinao Oda and Masaru Morita and Yoshihiko Maehara",
year = "2015",
month = "9",
day = "7",
doi = "10.1007/s12282-013-0515-x",
language = "English",
volume = "22",
pages = "520--528",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer

AU - Hisamatsu, Yuichi

AU - Tokunaga, Eriko

AU - Yamashita, Nami

AU - Akiyoshi, Sayuri

AU - Okada, Satoko

AU - Nakashima, Yuichiro

AU - Taketani, Kenji

AU - Aishima, Shinichi

AU - Oda, Yoshinao

AU - Morita, Masaru

AU - Maehara, Yoshihiko

PY - 2015/9/7

Y1 - 2015/9/7

N2 - Background: Determining the indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)-positive/HER2-negative breast cancer are difficult. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) are crucial for the hormone responsive phenotype of breast cancer. This study evaluated whether the expression of GATA-3 and FOXA1 is a prognostic and predictive marker of outcomes in patients with HR-positive/HER2-negative breast cancer. Methods: The expression of GATA-3 and FOXA1 was analyzed immunohistochemically in 214 patients with invasive breast cancer to evaluate the association with the clinicopathological features and the prognosis. Results: GATA-3 expression was positively correlated with FOXA1 expression (P < 0.0001). Both GATA-3 and FOXA1 were positively correlated with ER (P < 0.0001 each) and PR expression (P = 0.0001 and P = 0.0009, respectively), and inversely correlated with nuclear grade (P = 0.0002 and P = 0.0018, respectively) and Ki67 index (P = 0.0052 and P = 0.0049, respectively). Expression of GATA-3 and FOXA1 was associated with better prognosis. FOXA1 was an independent favorable prognostic marker in HR-positive/HER2-negative breast cancer. Disease-free survival rates were similar in patients with HR-positive/HER2-negative breast cancer and high FOXA1 expression given adjuvant hormone therapy (HT) alone and those given CT plus HT. Conclusion: GATA-3 and FOXA1 are associated with a less aggressive phenotype and a better prognosis in patients with HR-positive/HER2-negative breast cancer. FOXA1 may be useful in identifying those patients who may not require adjuvant CT.

AB - Background: Determining the indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)-positive/HER2-negative breast cancer are difficult. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) are crucial for the hormone responsive phenotype of breast cancer. This study evaluated whether the expression of GATA-3 and FOXA1 is a prognostic and predictive marker of outcomes in patients with HR-positive/HER2-negative breast cancer. Methods: The expression of GATA-3 and FOXA1 was analyzed immunohistochemically in 214 patients with invasive breast cancer to evaluate the association with the clinicopathological features and the prognosis. Results: GATA-3 expression was positively correlated with FOXA1 expression (P < 0.0001). Both GATA-3 and FOXA1 were positively correlated with ER (P < 0.0001 each) and PR expression (P = 0.0001 and P = 0.0009, respectively), and inversely correlated with nuclear grade (P = 0.0002 and P = 0.0018, respectively) and Ki67 index (P = 0.0052 and P = 0.0049, respectively). Expression of GATA-3 and FOXA1 was associated with better prognosis. FOXA1 was an independent favorable prognostic marker in HR-positive/HER2-negative breast cancer. Disease-free survival rates were similar in patients with HR-positive/HER2-negative breast cancer and high FOXA1 expression given adjuvant hormone therapy (HT) alone and those given CT plus HT. Conclusion: GATA-3 and FOXA1 are associated with a less aggressive phenotype and a better prognosis in patients with HR-positive/HER2-negative breast cancer. FOXA1 may be useful in identifying those patients who may not require adjuvant CT.

UR - http://www.scopus.com/inward/record.url?scp=84940954066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940954066&partnerID=8YFLogxK

U2 - 10.1007/s12282-013-0515-x

DO - 10.1007/s12282-013-0515-x

M3 - Article

C2 - 24415069

AN - SCOPUS:84940954066

VL - 22

SP - 520

EP - 528

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 5

ER -